Retrophin (NASDAQ:RTRX) Lifted to Buy at BidaskClub

BidaskClub upgraded shares of Retrophin (NASDAQ:RTRX) from a hold rating to a buy rating in a report issued on Saturday, BidAskClub reports.

Several other brokerages also recently issued reports on RTRX. BTIG Research assumed coverage on shares of Retrophin in a research note on Tuesday, June 16th. They issued a buy rating and a $25.00 price objective for the company. Canaccord Genuity reissued a buy rating and issued a $26.00 price objective on shares of Retrophin in a research note on Tuesday, May 19th. BMO Capital Markets raised their price objective on shares of Retrophin from $33.00 to $34.00 and gave the stock an outperform rating in a research note on Tuesday, May 12th. ValuEngine downgraded shares of Retrophin from a strong-buy rating to a buy rating in a research note on Friday, April 17th. Finally, Zacks Investment Research raised shares of Retrophin from a hold rating to a buy rating and set a $16.00 price objective for the company in a research note on Monday, May 4th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $26.50.

RTRX opened at $20.41 on Friday. The firm has a market cap of $844.12 million, a P/E ratio of -8.33 and a beta of 0.81. Retrophin has a 12 month low of $8.98 and a 12 month high of $21.95. The company has a current ratio of 5.97, a quick ratio of 5.88 and a debt-to-equity ratio of 0.92. The stock has a 50-day moving average of $16.32 and a 200 day moving average of $15.36.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $0.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.68) by $0.70. The company had revenue of $47.77 million during the quarter, compared to analyst estimates of $43.14 million. Retrophin had a negative return on equity of 43.15% and a negative net margin of 57.01%. On average, research analysts forecast that Retrophin will post -1.56 earnings per share for the current fiscal year.

In other news, Director Steve Aselage sold 10,000 shares of Retrophin stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00. Following the completion of the sale, the director now owns 238,732 shares of the company’s stock, valued at $4,774,640. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 16,364 shares of company stock valued at $298,850 in the last ninety days. Insiders own 4.63% of the company’s stock.

A number of large investors have recently modified their holdings of RTRX. Nisa Investment Advisors LLC raised its stake in Retrophin by 103.1% in the first quarter. Nisa Investment Advisors LLC now owns 1,970 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,000 shares in the last quarter. Great West Life Assurance Co. Can bought a new position in Retrophin in the fourth quarter worth approximately $50,000. SG Americas Securities LLC bought a new position in Retrophin in the first quarter worth approximately $122,000. Calton & Associates Inc. bought a new position in Retrophin in the first quarter worth approximately $158,000. Finally, Caxton Associates LP bought a new position in Retrophin in the fourth quarter worth approximately $161,000.

About Retrophin

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

See Also: What is the CAC 40 Index?

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.